- This event has passed.
MAKING YOUR EXIT
April 8 @ 1:00 pm - 2:00 pm UTC-7
It’s never too early to start thinking about your exit strategy. Knowing where you’re going will help you take the necessary steps to achieve the highest valuation possible. You’ve got options! During this panel discussion we’ll discuss the classic IPO path as well as direct offerings, reverse mergers and Special Purpose Acquisition Companies (SPACs) which have become increasingly popular. Join us to learn how to identify and mitigate potential risks that could diminish the value of your company or IP.
Michael Hostetler, PhD, Esq., Partner, Wilson Sonsini Goodrich & Rosati
Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development.
Andrew McDonald, PhD, Founding Partner at LifeSci Venture Partners
Andrew McDonald is an experienced healthcare investment professional with expertise in identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Partners. Prior to founding LifeSci, Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials.
Megan Baier, Esq., Partner, Corporate at Wilson Sonsini
Megan Baier focuses on corporate and securities law, including general corporate representation, public offerings, venture capital financings, and mergers and acquisitions within the life sciences, healthcare, and technology sectors. Megan has assisted with matters ranging from formation and early-stage venture financing to listings of publicly traded securities on U.S. exchanges. She also has extensive experience representing leading investment banks and corporate issuers in connection with public offerings. She also has considerable experience counseling on general corporate representation, mergers and acquisitions, SEC compliance, disclosure matters, and complex securities law issues.
Winston Kung, COO & CFO, PMVPharma
Prior to joining PMV Pharma, Mr. Kung was a Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer at Celgene Cellular Therapeutics (CCT). Over four and a half years, he led the formation of a strategic long range plan for CCT, multiple transactions and a team that managed Celgene’s alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group.